Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma, T-Cell, Peripheral 9Lymphoma, T-Cell, Cutaneous 6Lymphoma, T-Cell 6Lymphoma 6Sezary Syndrome 3Mycosis Fungoides 3Multiple Myeloma 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Hematologic Neoplasms 2Waldenstrom Macroglobulinemia 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Oligodendroglioma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Malignant mesenchymal tumor 1

Interventions

Carboplatin 25Bevacizumab 18Paclitaxel 17Pemetrexed 16Erlotinib Hydrochloride 14Radiotherapy 12Docetaxel 9Gemcitabine 7Cisplatin 6ceritinib 5Taxes 5Cetuximab 5pembrolizumab 3pegfilgrastim 3capmatinib 3Surgical Procedures, Operative 3Radiosurgery 3Metformin 3Gefitinib 3Cyclophosphamide 3Thalidomide 2Sorafenib 2Radiotherapy, Conformal 2Nivolumab 2Immunoglobulin G 2Filgrastim 2Disulfides 2Albumin-Bound Paclitaxel 25-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide 2veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma of Lung × romidepsin × Clear all
NCT01302808 2021-01-20

Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

University of Texas Southwestern Medical Center

Phase 1 Completed
17 enrolled 12 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡